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ABSTRACT The recombinant hormone obtained by non-
covalent interaction of the NH-terminal 134 amino acid frag-
ment with the COOH-terminal 51 amino acid fragment of the
reduced-carbamidomethylated human somatotropin molecule
is found to exhibit nearly full biological activity of the native
hormone, as evidenced by the stimulation of hepatic ornithine
decarboxylase (L-ornithine carboxy-lyase, EC 4.1.1.17) in vivo
and protein synthesis in mouse mammary gland in vitro. Ra-
dioimmunoassay data indicate that the recombinant behaves
immunochemically in a manner almost identical to that of the
native hormone.
It has been reported that hydrolysis of human somatotropin
(HGH) with human plasmin does not cause any changes in the
biological properties of the hormone (1-5). The predominant
action of plasmin on HGH is the cleavage of the Arg-Thr and
Lys-Gln bonds at positions 134-135 and 140-141, respectively
(see Fig. 1). Thus, the main product of a limited plasmin di-
gestion of the hormone is composed of the NH2-terminal por-
tion (residues 1-134) and the COOH-terminal portion (residues
141-191) of HGH. These are connected to each other by a di-
sulfide linkage at sequence positions 53 and 165. The removal
of the hexapeptide (residues 135-140) from the structure of
HGH does not alter the conformation of the molecule as evi-
denced by circular dichroism spectra (6).
When plasmin-modified HGH is submitted to reduction and
alkylation, two peptide fragments are separated by exclusion
chromatography on Sephadex G-50 in 10% (wt/vol) acetic acid:
[Cys(Cam)53-HGH-(1-134)] and [Cys(Cam)l165s82,189-HGH-
(141-191)] (Cam is carbamidomethyl). Bioassay data showed
both fragments to be biologically active (4). The biological
activity of the NH2-terminal 1-134 fragment is about 14% of
that for native HGH by both the rat tibia and pigeon crop-sac
tests. The COOH-terminal 141-191 fragment also exhibits ac-
tivity in both tests, although it is less active than the NH2-ter-
minal fragment. Complement fixation and radioimmunoassay
experiments showed that the NH2-terminal fragment is also
more immunoreactive (7). We reported recently the restoration
of full rat tibia and pigeon crop-sac stimulating activities by
noncovalent interaction of these two fragments of HGH (8).
This communication describes biological and immunochemical
properties of the recombinant HGH molecule and supports the
conclusion that the recombinant possesses full or nearly full
HGH activity.
MATERIALS AND METHODS
Human somatotropin was isolated from fresh-frozen pituitary
glands as previously described (9). Cys(Cam)53-HGH-(1-134)
and Cys(Cam)165,182'189-HGH-(141-191) were prepared from
Table 1. Stimulation of hepatic ornithine decarboxylase
activity by the recombinant obtained by noncovalent
interaction of the two fragments of HGH
Ornithine
Dose decarboxylase
Preparation (nmol) activity*
Saline 0.0 16.5 ± 6.6
HGH 0.045 60.8 ± 15.4
0.135 126.8 ± 8.3
Recombinant t 0.047 21.0 ± 5.9
0.141 113.2 ± 16.0
* Values (pmol of 14CO2 released per mg of protein per hr) in mean
i SEM. Four rats were in each group.
t Potency relative to HGH was 69% with 95% confidence limit of
43-98% and A = 0.15.
plasmin digests of HGH as previously described (4) except that
the NH2-terminal fragment was further purified by gel fil-
tration on Sephadex G-100 in 0.01 M NH4HCO3 of pH 8.2. The
recombinant HGH was prepared by the procedure recently
published (8). DL-['4C]ornithine monohydrochloride (7.6
mCi/mmol) and [3H]leucine (5.0 Ci/mmol) were obtained
from New England Nuclear Corp.
For radioimmunoassay, the double-antibody procedure of
Schalch and Reichlin (10) was used with slight modification,
employing a guinea pig antiserum to native HGH. Highly
purified HGH (9) was used for the preparation of standards and
labeling with '31I according to the procedure of Greenwood et
al. (11). The hepatic ornithine decarboxylase activity (L-orni-
thine carboxy-lyase, EC 4.1.1.17) was assayed by the procedure
Table 2. Stimulation of protein synthesis in mouse
mammary gland in vitro by the recombinant obtained by
noncovalent interaction of the two fragments of HGH
[3H ] Leucine
incorporation t
Concentra- (cpm/mg of
tion* protein)
Preparation (g/ml) (x 10-4)
Control 0 1.88 ± 0.30
HGH 22.5 3.34 ± 0.34
67.5 5.44 ± 0.31
Recombinantf 22.5 3.63 ± 0.27
67.5 5.07 t 0.35
* Three daily treatments; concentrations are final concentrations.
t Mean + SEM from five replicates.
I Potency relative to HGH., 97% with 95% confidence limit of 60-
116% and A = 0.20.
Abbreviation: HGH, human somatotropin (growth hormone); Cam,
carbamidomethyl.
* This is paper no. 50 in a series. Paper no. 49 is ref. 15.
3463
Proc. Natl. Acad. Sci. USA 73 (1976)
FIG. 1. Amino acid sequence of the HGH molecule.
of Janne and Williams-Ashman (12) in male rats, 21 days of age,
of the Sprague-Dawley strain. Prolactin activity was estimated
by using a modification of the mammary gland bioassay pre-
viously described (13). In this bioassay, prolactins specifically
stimulate the incorporation of tritium-labeled leucine into tri-
chloroacetic-acid-precipitable proteins in organ-cultured
mammary tissues of mid-pregnant BALB/c mice.
RESULTS AND DISCUSSION
Table 1 summarizes the results of the ornithine-decarboxyl-
ase-stimulating activity of the recombinant. In comparison with
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the activity of the native hormone, the recombinant possesses
69% of HGH potency. Earlier studies (14) showed that the
NH2-terminal fragment had only 10% potency of the native
hormone and the COOH-terminal fragment was inactive at the
highest dose tested (120 nmol).
It may be seen in Table 2 that the recombinant had 97%
potency of HGH in stimulating protein synthesis in mouse
mammary gland in vitro. This is in agreement with the earlier
experiment (8) in which the recombinant exhibits full prolactin
activity of HGH as assayed by the pigeon crop-sac method.
Figure 2 presents the radioimmunoassay results with un-
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FIG. 2. Competition of the recombinant and human somatotropin in the HGH radioimmunoassay system. Final dilution of guinea pig an-
tiserum was 1/140,000.
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purified and purified recombinants using guinea pig antiserum.
It may be noted that the unpurified recombinant showed much
stronger inhibition than that obtained with the NH2-terminal
fragment (Fig. 2A). After purification, the recombinant gave
inhibition curves which were nearly identical to that of HGH
standard (Fig. 2B). There is a slight lack of parallelism shown
by the slope of inhibition of the purified or non-purified re-
combinant and that of HGH. This may be due to the fact that
the recombinant is missing the hexapeptide Thr-Gly-Gln-Ile-
Phe-Lys from residues 135-140 (see Fig. 1) and the two disulfide
bridges. It may also be noted that the HGH control (Fig. 2A)
showed no detectable effect on the immunoreactivity of native
HGH subjected to the same conditions of storage undergone
by the fragments during the formation of the recombinant. It
was fortuitous that the conditions which facilitated the for-
mation of the recombinant such as the pH (8.4) and the tem-
perature (40) were the same conditions utilized in the ra-
dioimmunoassay, thus minimizing or preventing the dissocia-
tion of the recombinant during the assay.
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